Clinical Trial

Effect of add-on Doxofylline on Lung Function in Stable COPD

Study acronym: EDAI
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
It is a phase IV, prospective, interventional, single blind, randomized, crossover trial in which the investigators will evaluate the effects of a 4-week treatment with doxofylline 400 mg bid, in add-on to maximal inhalation therapy, in clinically stable COPD patients.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-01-19; most recent amendment 2026-04-28.
Trial Details
NCT Number NCT04238221
Lead Sponsor University of Milan
Conditions Chronic Obstructive Pulmonary Disease
Enrollment 78 participants
Start Date 2026-12-01
Primary Completion 2027-12-01 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-29